Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group

ABSTRACT:

SUBMITTER: Quinquenel A 

PROVIDER: S-EPMC12770953 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature